US FDA approves Roche’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer

發(fā)布時(shí)間： 2021-10-21 閱讀：652次

分享

October 15, 2021 – Roche today announced that the US Food and Drug Administration (FDA) has approved Tecentriq? (atezolizumab) as adjuvant treatment, following surgery and platinum-based chemotherapy, for adults with Stage II-IIIA non-small cell lung cancer (NSCLC) whose tumours express PD-L1≥1%, as determined by an FDA-approved test.

Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting.

Approval is based on the Phase III IMpower010 study showing adjuvant Tecentriq improved disease-free survival by more than one-third in PD-L1-positive Stage II-IIIA lung cancer, compared with best supportive care.

“Too many patients with early-stage lung cancer experience disease recurrence following surgery. Now, the availability of immunotherapy following surgery and chemotherapy offers many patients new hope and a powerful new tool to reduce their risk of cancer relapse,” said Bonnie Addario, Co-founder and Chair, GO2 Foundation for Lung Cancer. “With this approval, it is more important than ever to screen for lung cancer early and test for PD-L1 at diagnosis to help bring this advance to the people who can benefit.”